Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia.

Tsai DE, Luger SM, Andreadis C, Vogl DT, Kemner A, Potuzak M, Goradia A, Loren AW, Perl AE, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Thompson JE, Swider C, Bagg A, Mato AR, Carroll M.

Clin Cancer Res. 2008 Sep 1;14(17):5619-25. doi: 10.1158/1078-0432.CCR-07-5185.

2.

Evidence of myeloid differentiation in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene.

Tsai DE, Luger SM, Kemner A, Swider C, Goradia A, Tomczak E, DiPatri D, Bagg A, Nowell P, Loren AW, Perl A, Schuster S, Thompson JE, Porter D, Andreadis C, Stadtmauer EA, Goldsteini S, Ghalie R, Carroll M.

Cancer Biol Ther. 2007 Jan;6(1):18-21.

PMID:
17204865
3.

Differentiation syndrome in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene.

DiNardo CD, Ky B, Vogl DT, Forfia P, Loren A, Luger S, Mato A, Tsai DE.

Med Oncol. 2008;25(3):299-302. doi: 10.1007/s12032-007-9035-x. Epub 2008 Jan 8.

PMID:
18181037
4.

Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.

Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C.

Leuk Res. 2008 Dec;32(12):1830-6. doi: 10.1016/j.leukres.2008.04.026. Epub 2008 Jun 20.

PMID:
18571721
5.

Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.

Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC; Worldwide Bexarotene Study Group.

Arch Dermatol. 2001 May;137(5):581-93.

PMID:
11346336
6.

Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides.

Papadavid E, Antoniou C, Nikolaou V, Siakantaris M, Vassilakopoulos TP, Stratigos A, Stavrianeas N, Katsambas A.

Am J Clin Dermatol. 2008;9(3):169-73.

PMID:
18429646
7.

Expanding the use of retinoids in acute myeloid leukemia: spotlight on bexarotene.

McNamara S, Miller WH Jr.

Clin Cancer Res. 2008 Sep 1;14(17):5311-3. doi: 10.1158/1078-0432.CCR-08-1081. No abstract available.

8.

Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia.

Löwenberg B, Morgan G, Ossenkoppele GJ, Burnett AK, Zachée P, Dührsen U, Dierickx D, Müller-Tidow C, Sonneveld P, Krug U, Bone E, Flores N, Richardson AF, Hooftman L, Jenkins C, Zweegman S, Davies F.

J Clin Oncol. 2010 Oct 1;28(28):4333-8. doi: 10.1200/JCO.2009.27.6295. Epub 2010 Aug 23.

PMID:
20733120
9.

A phase I study of bexarotene and rosiglitazone in patients with refractory cancers.

Read WL, Baggstrom MQ, Fracasso PM, Govindan R.

Chemotherapy. 2008;54(3):236-41. doi: 10.1159/000140468. Epub 2008 Jun 18.

PMID:
18560232
10.

A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.

Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Frey NV, Nasta SD, Hexner EO, Dierov JK, Swider CR, Bagg A, Gewirtz AM, Carroll M, Luger SM.

Clin Cancer Res. 2009 Nov 1;15(21):6732-9. doi: 10.1158/1078-0432.CCR-09-0842. Epub 2009 Oct 20.

11.

Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.

Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, Romanski A, Kramer OH, Kampfmann M, Hoelzer D, Neubauer A, Ruthardt M, Ottmann OG.

Cancer. 2005 Dec 15;104(12):2717-25.

12.

Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995.

Gordon MS, Young ML, Tallman MS, Cripe LD, Bennett JM, Paietta E, Longo W, Gerad H, Mazza J, Rowe JM.

Leuk Res. 2000 Oct;24(10):871-5.

PMID:
10996206
13.

Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study.

Fassas A, Buffels R, Anagnostopoulos A, Gacos E, Vadikolia C, Haloudis P, Kaloyannidis P.

Br J Haematol. 2002 Feb;116(2):308-15.

PMID:
11841431
14.

Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.

Karp JE, Passaniti A, Gojo I, Kaufmann S, Bible K, Garimella TS, Greer J, Briel J, Smith BD, Gore SD, Tidwell ML, Ross DD, Wright JJ, Colevas AD, Bauer KS.

Clin Cancer Res. 2005 Dec 1;11(23):8403-12.

15.

Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.

Roboz GJ, Giles FJ, Ritchie EK, Allen-Bard S, Curcio TJ, Wilkes MA, Park SL, Kantarjian HM, Faderl S, Ravandi F, Kelner MJ, Feldman EJ.

J Clin Oncol. 2007 Jan 1;25(1):10-5. Epub 2006 Dec 4.

PMID:
17146106
16.

Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia.

Vahdat L, Wong ET, Wile MJ, Rosenblum M, Foley KM, Warrell RP Jr.

Blood. 1994 Nov 15;84(10):3429-34.

17.
18.

Bexarotene therapy for mycosis fungoides and Sézary syndrome.

Abbott RA, Whittaker SJ, Morris SL, Russell-Jones R, Hung T, Bashir SJ, Scarisbrick JJ.

Br J Dermatol. 2009 Jun;160(6):1299-307. doi: 10.1111/j.1365-2133.2009.09037.x. Epub 2009 Feb 16.

PMID:
19222457
19.

Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia.

Bieker R, Lerchenmüller C, Wehmeyer J, Serve HL, Mesters RM, Büchner T, Berdel WE.

Oncol Rep. 2003 Jul-Aug;10(4):915-20.

PMID:
12792745
20.

Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma.

Querfeld C, Rosen ST, Guitart J, Rademaker A, Fung BB, Posten W, Kuzel TM.

J Am Acad Dermatol. 2004 Jul;51(1):25-32.

PMID:
15243520

Supplemental Content

Support Center